electroCore (ECOR) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Thu, May 7, 2026 astatine 9:15 AM CDT 37 min read

Image source: The Motley Fool.

DATE

Wednesday, May 6, 2026 astatine 4:30 p.m. ET

CALL PARTICIPANTS

• Interim President — Thomas Errico

• Chief Operating Officer — Michael Fox

• Chief Financial Officer — Joshua S. Lev

Need a punctuation from a Motley Fool analyst? Email [email protected]

Full Conference Call Transcript

Thomas Errico: Good afternoon, everyone, and convey you for joining electroCore, Inc.'s archetypal 4th 2026 net call. This is the archetypal net telephone since we announced our enactment transition, and I privation to instrumentality a infinitesimal to stock however encouraged I americium by the advancement we person made executing that modulation and by the momentum we proceed to spot crossed the organization. Since stepping into the relation of interim president, Josh has provided steady, disciplined enactment portion maintaining his absorption connected fiscal rigor. The alignment betwixt our operational priorities and our fiscal strategy has been evident, and the enactment has responded with absorption and urgency. The strategy has not changed. The execution has not slowed.

If anything, the absorption crossed the enactment has sharpened. At the aforesaid time, Michael Fox joined america arsenic main operating serviceman connected April 13, bringing much than 35 years of commercialized enactment acquisition crossed analyzable healthcare markets, including extended enactment wrong the national systems and the U.S. Department of Veteran Affairs. In conscionable 3 weeks, his extent of acquisition has already provided invaluable insights to fortify our execution, peculiarly arsenic we proceed to grow our beingness wrong analyzable authorities channels. He volition present himself shortly. Importantly, this modulation has not slowed america down. It has reinforced our foundations.

We stay firmly committed to our strategy: driving maturation wrong our covered entities, advancing our objective and technological enactment successful noninvasive vagus nervus stimulation, and expanding our scope into the user wellness market. And we are doing truthful with discipline, managing the outgo base, expanding the margin, and protecting our way to profitability. In our objective work, we proceed to put successful the grounds basal that underpins our portfolio. That grounds remains a cardinal differentiator arsenic we prosecute with providers, payers, and partners globally arsenic good arsenic domestically, and it positions america to grow into caller indications implicit time. In the VA, we person built a credible commercialized beingness implicit galore years. We judge we person a meaningful semipermanent opportunity.

Our commercialized enactment is leveraging Mike's acquisition to place caller ways to beryllium much targeted and much effective, peculiarly wrong a strategy wherever we inactive person important country to penetrate. On the user side, we are gathering a scalable, direct-to-consumer transmission with expanding marque visibility, improving portion economics, and a increasing web of influencer and affiliate partners that resonate with audiences seeking nonpharmacologic, science-backed wellness solutions. The aboriginal traction we are seeing reinforces our content successful the broader applicability of our exertion and its relevance to mundane wellness. What gives maine the top assurance is not conscionable the advancement itself, but however it is being achieved—with discipline, alignment, and a wide consciousness of intent crossed the organization.